California State Teachers Retirement System Cuts Stock Position in IQVIA Holdings Inc. $IQV

California State Teachers Retirement System trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 254,847 shares of the medical research company's stock after selling 6,584 shares during the quarter. California State Teachers Retirement System owned 0.15% of IQVIA worth $49,241,537 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in IQV. Financial Freedom LLC purchased a new stake in shares of IQVIA during the first quarter worth $25,000. Ascentis Independent Advisors acquired a new stake in shares of IQVIA during the first quarter worth $25,000. International Assets Investment Management LLC acquired a new position in IQVIA during the fourth quarter worth about $27,000. Compass Financial Management LLC purchased a new position in shares of IQVIA during the 2nd quarter valued at $27,000. Finally, Elevation Wealth Partners LLC raised its position in shares of IQVIA by 218.8% during the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company's stock valued at $30,000 after buying an additional 105 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of IQVIA stock traded up $4.99 during midday trading on Tuesday, reaching $270.66. The company had a trading volume of 713,335 shares, compared to its average volume of 1,717,920. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $272.35. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $44.55 billion, a price-to-earnings ratio of 33.56, a price-to-earnings-growth ratio of 2.24 and a beta of 1.18. The stock has a fifty day simple moving average of $237.75 and a 200 day simple moving average of $196.87.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same period in the prior year, the firm posted $2.81 EPS. IQVIA's quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

Insider Transactions at IQVIA

In related news, insider Keriann Cherofsky sold 558 shares of the company's stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider owned 2,989 shares of the company's stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Bhavik Patel sold 1,855 shares of the company's stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider directly owned 1,348 shares of the company's stock, valued at approximately $317,143.96. This represents a 57.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 15,581 shares of company stock valued at $3,796,021. Company insiders own 1.70% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on IQV. TD Cowen lifted their price target on IQVIA from $233.00 to $288.00 and gave the stock a "buy" rating in a report on Wednesday, July 29th. Stifel Nicolaus boosted their price target on shares of IQVIA from $220.00 to $276.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. BMO Capital Markets upped their price objective on IQVIA from $210.00 to $270.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 29th. Morgan Stanley reissued an "equal weight" rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Finally, Barclays reiterated an "overweight" rating on shares of IQVIA in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $243.62.

About IQVIA

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.